[Dibekacin in bronchopulmonary infectious pathology].

Thirty six patients in an intensive care unit with a bacterial bronchopulmonary infection were treated with intraparenteral dibekacin at a dose of 3 mg/kg/day. Mean age of the patients was 55 years and the mean duration of treatment 14 days. Biological material was obtained by fibro-aspiration or pleural tap. One or more organisms were identified in 36 cases. These were essentially staphylococci and Gram negative bacilli sensitive to dibekacin. Results showed a favourable course in 26 cases and a clinical improvement in 10. Clinical and biological tolerance was good. No clinical manifestations of cochleo-vestibular toxicity were seen.